News

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills
The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...
Novo Nordisk Says Its 'Wegovy In A Pill' Delivers Big: '16.6% Average' Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesity
Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...
Wall Street Journal16d
Novo Nordisk Says FDA Accepted New Drug Application for Wegovy Pill
Novo Nordisk NOVO.B3.59%increase; green up pointing triangle said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a ...
Yahoo Finance5d
Novo Nordisk, Septerna sign $2.2B deal to develop weight-loss pill
Pharmaceutical giant Novo Nordisk inks a $2.2 billion deal with biotech company Septerna to develop a GLP-1 weight-loss drug in the form of an oral pill.Septerna's stock is skyrocketing by over ...
MarketWatch27d
Novo Nordisk Shares Fall After Data From New Eli Lilly Pill
Novo Nordisk shares fell Tuesday after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant's blockbuster shots. Shares fell as much as 9.8% ...
NJBIZ13d
Novo Nordisk seeks FDA approval for Wegovy weight loss pill
Novo Nordisk said it expects a decision by the fourth quarter of this year. The pharma giant already has one GLP-1 available in pill form under the name Rybelsus. The FDA cleared that drug in ...
Novo Nordisk announces CEO transition as share price slips
After nearly tripling the company’s value, CEO Lars Fruergaard Jørgensen is preparing to exit amid boardroom shifts. Novo Nordisk announced Friday that it would part ways with its longtime CEO, who ...